PharmaCielo Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Marc Lustig
- Full Time Employees
- 268
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 82 Richmond Street East Toronto ON Canada M5C 1P1
- IPO Date
- Jan 30, 2018
- Website
- pharmacielo.com
- Similar Companies
- Business
- PharmaCielo Ltd. engages in the ethical and sustainable cultivation, processing, and supply of medicinal-grade cannabis products. The company produces medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis, and other related products, alongside telemedicine software solutions. PharmaCielo primarily serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies across multiple global markets, including Canada, Latin America, Africa, and emerging Asian markets. The company operates through its subsidiary PharmaCielo Colombia Holdings S.A.S. and is headquartered in Toronto, Canada. PharmaCielo recently achieved significant sales growth, notably a 143% year-over-year increase resulting in a total revenue of CAD 3.54 million for the fiscal year ending 2024, accompanied by improved gross profit margins and adjusted EBITDA gains due to a more diverse customer base and cost reductions. Key strategic developments include a binding letter of intent to acquire Siam Ventures, a contract manufacturing business based in Thailand, which establishes PharmaCielo’s entry into large Asian markets and broadens its manufacturing capabilities. The company's board will be strengthened by the addition of Siam Ventures' Chairman and CEO post-acquisition. Furthermore, PharmaCielo formed a strategic partnership with Benuvia Operations, LLC to produce current Good Manufacturing Practice (cGMP) and European Union-Good Manufacturing Practice (EU-GMP) pharmaceutical-grade active pharmaceutical ingredients (APIs), enabling expansion into global pharmaceutical markets such as Brazil, Australia, Europe, and the United States. Additional recent operational updates include the completion of the sale of its La Margarita land asset to repay a significant loan and strengthen its balance sheet, allowing focus on high-value sales pipeline expansion. PharmaCielo’s product distribution has extended to 12 countries, including first shipments to Morocco, providing entry into African and broader international markets. Founded in 2014, the company continues to build on its position as a premier global supplier of pharmaceutical-grade cannabis extracts, with ongoing efforts to broaden its product portfolio beyond CBD isolate and to meet increasing global demand for reliable, high-quality medicinal cannabis products.
Company News
PharmaCielo Announces 2026 First Quarter Results
PharmaCielo Announces 2026 Year-End Results
PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge Financing
PharmaCielo Announces Intention to Issue Interest Shares
PharmaCielo Announces the Issuance of Interest Shares
PharmaCielo Announces 2025 Q3 Results, AGM Details
PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares
PharmaCielo Announces Revocation of FFCTO and Related Corporate Matters
PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes Audit
PharmaCielo Announces Issuance of Cease Trade Order
PharmaCielo Reports Q4 2024 Financial Results
PharmaCielo Announces Issuance of Shares for Settlement of Certain Amounts Owing
PharmaCielo Reports Q3 2024 Financial Results
PharmaCielo Announces Intention to Extend Expiry Date of Warrants
PharmaCielo Announces Change to Financial Year-End, and Appointment of Davidson & Company LLP as Auditor Effective October 7, 2024
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2024
CORRECTION FROM SOURCE: PharmaCielo Provides Update on Reinstatement for Trading
PharmaCielo Provides Update on Reinstatement for Trading
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023, and the First Quarter Ended March 31, 2024
PharmaCielo Announces Issuance of Failure to File Cease Trade Order